Market Cap 14.37B
Revenue (ttm) 2.36B
Net Income (ttm) 341.30M
EPS (ttm) N/A
PE Ratio 35.13
Forward PE 28.36
Profit Margin 14.49%
Debt to Equity Ratio 0.00
Volume 642,900
Avg Vol 949,610
Day's Range N/A - N/A
Shares Out 99.71M
Stochastic %K 24%
Beta 0.22
Analysts Strong Sell
Price Target $174.46

Company Profile

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat cong...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 858 617 7600
Address:
12780 El Camino Real, San Diego, United States
PrivateProfiteer
PrivateProfiteer Nov. 15 at 12:08 AM
$NBIX is currently trading at $144.86, showing a neutral RSI of 45.09, indicating no immediate overbought or oversold conditions. The price is above both the 30-day MA of 142.95 and the 50-day MA of 142.64, suggesting a bullish short-term trend. However, the absence of a 200-day MA limits long-term trend analysis. The recent 60-day high of 157.67 and low of 133.61 indicates a significant range. The ATR of 5.92 suggests moderate volatility, allowing for reasonable price movement. Directional bias leans bullish due to the price being above key moving averages. Suggested entry is at $145.50, with a stop loss at $140.00 to manage risk. Target 1 is set at $150.00, aligning with psychological resistance, and Target 2 at $155.00, near the recent high. Monitor market conditions closely, as price action near the targets may require adjustments. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 3:42 AM
$NBIX: The last close at $144.16 shows a stable position within the 60-day high of $157.67 and low of $132.41. The RSI at 50.18 indicates a neutral momentum, suggesting neither overbought nor oversold conditions. The price is above both the 30-day MA of $142.69 and the 50-day MA of $142.63, indicating a potential bullish trend. Directional bias is cautiously optimistic due to the price being above key moving averages, which may support upward movement. Suggested entry is at $145.00, slightly above the last close to confirm bullish sentiment. Set a stop loss at $138.00, below the recent low to manage risk. Targets are set at $150.00 (near the 60D high) and $155.00, allowing for potential profit-taking while monitoring market conditions. Overall, the trade plan reflects a balanced approach with defined risk and reward parameters. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 1:49 AM
$NBIX is currently trading at $147.29, showing a moderate RSI of 56.44, indicating a neutral to slightly bullish momentum. The price is above both the 30-day MA of 142.11 and the 50-day MA of 142.34, suggesting a bullish trend in the short to medium term. The recent high of 157.67 is significantly above the last close, providing a potential target for upward movement, while the low of 131.91 establishes a solid support level. Trade Plan: - Directional Bias: Bullish - Suggested Entry: $148.00 (above the last close to confirm upward momentum) - Stop: $142.00 (below the recent MAs for risk management) - Target 1: $155.00 (near the 60D high) - Target 2: $157.00 (slightly below the 60D high for a conservative exit) Monitor the ATR of 5.91 for volatility and adjust stop levels accordingly. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 1:25 AM
$NBIX is currently trading at $147.29, showing a moderate RSI of 56.44, indicating a neutral to slightly bullish momentum. The price is above both the 30-day MA of 142.11 and the 50-day MA of 142.34, suggesting a bullish trend in the short to medium term. The recent high of 157.67 is significantly above the last close, providing a potential target for upward movement, while the low of 131.91 establishes a solid support level. Trade Plan: - Directional Bias: Bullish - Suggested Entry: $148.00 (above the last close to confirm upward momentum) - Stop: $142.00 (below the recent MAs for risk management) - Target 1: $155.00 (near the 60D high) - Target 2: $157.00 (slightly below the 60D high for a conservative exit) Monitor the ATR of 5.91 for volatility and adjust stop levels accordingly. https://privateprofiteers.com
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 11 at 3:52 PM
Results List 11/2025 13 days to go. $MTSI $MTSR $MULL $MYRG $NBIX 🔥
0 · Reply
JarvisFlow
JarvisFlow Nov. 11 at 12:43 PM
Morgan Stanley has updated their rating for Neurocrine Biosciences ( $NBIX ) to Overweight with a price target of 173.
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Nov. 10 at 10:03 PM
1 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 9 at 10:31 PM
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 6 at 4:05 PM
0 · Reply
GoIrish1776
GoIrish1776 Nov. 6 at 2:44 PM
$NBIX Teva Pharmaceuticals CEO on earnings beat: Our shift to biopharma is working (Information on IRA discussion) https://www.cnbc.com/video/2025/11/05/teva-pharmaceuticals-ceo-on-earnings-beat-our-shift-to-biopharma-is-working.html
0 · Reply
Latest News on NBIX
PrivateProfiteer
PrivateProfiteer Nov. 15 at 12:08 AM
$NBIX is currently trading at $144.86, showing a neutral RSI of 45.09, indicating no immediate overbought or oversold conditions. The price is above both the 30-day MA of 142.95 and the 50-day MA of 142.64, suggesting a bullish short-term trend. However, the absence of a 200-day MA limits long-term trend analysis. The recent 60-day high of 157.67 and low of 133.61 indicates a significant range. The ATR of 5.92 suggests moderate volatility, allowing for reasonable price movement. Directional bias leans bullish due to the price being above key moving averages. Suggested entry is at $145.50, with a stop loss at $140.00 to manage risk. Target 1 is set at $150.00, aligning with psychological resistance, and Target 2 at $155.00, near the recent high. Monitor market conditions closely, as price action near the targets may require adjustments. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 3:42 AM
$NBIX: The last close at $144.16 shows a stable position within the 60-day high of $157.67 and low of $132.41. The RSI at 50.18 indicates a neutral momentum, suggesting neither overbought nor oversold conditions. The price is above both the 30-day MA of $142.69 and the 50-day MA of $142.63, indicating a potential bullish trend. Directional bias is cautiously optimistic due to the price being above key moving averages, which may support upward movement. Suggested entry is at $145.00, slightly above the last close to confirm bullish sentiment. Set a stop loss at $138.00, below the recent low to manage risk. Targets are set at $150.00 (near the 60D high) and $155.00, allowing for potential profit-taking while monitoring market conditions. Overall, the trade plan reflects a balanced approach with defined risk and reward parameters. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 1:49 AM
$NBIX is currently trading at $147.29, showing a moderate RSI of 56.44, indicating a neutral to slightly bullish momentum. The price is above both the 30-day MA of 142.11 and the 50-day MA of 142.34, suggesting a bullish trend in the short to medium term. The recent high of 157.67 is significantly above the last close, providing a potential target for upward movement, while the low of 131.91 establishes a solid support level. Trade Plan: - Directional Bias: Bullish - Suggested Entry: $148.00 (above the last close to confirm upward momentum) - Stop: $142.00 (below the recent MAs for risk management) - Target 1: $155.00 (near the 60D high) - Target 2: $157.00 (slightly below the 60D high for a conservative exit) Monitor the ATR of 5.91 for volatility and adjust stop levels accordingly. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 1:25 AM
$NBIX is currently trading at $147.29, showing a moderate RSI of 56.44, indicating a neutral to slightly bullish momentum. The price is above both the 30-day MA of 142.11 and the 50-day MA of 142.34, suggesting a bullish trend in the short to medium term. The recent high of 157.67 is significantly above the last close, providing a potential target for upward movement, while the low of 131.91 establishes a solid support level. Trade Plan: - Directional Bias: Bullish - Suggested Entry: $148.00 (above the last close to confirm upward momentum) - Stop: $142.00 (below the recent MAs for risk management) - Target 1: $155.00 (near the 60D high) - Target 2: $157.00 (slightly below the 60D high for a conservative exit) Monitor the ATR of 5.91 for volatility and adjust stop levels accordingly. https://privateprofiteers.com
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 11 at 3:52 PM
Results List 11/2025 13 days to go. $MTSI $MTSR $MULL $MYRG $NBIX 🔥
0 · Reply
JarvisFlow
JarvisFlow Nov. 11 at 12:43 PM
Morgan Stanley has updated their rating for Neurocrine Biosciences ( $NBIX ) to Overweight with a price target of 173.
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Nov. 10 at 10:03 PM
1 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 9 at 10:31 PM
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 6 at 4:05 PM
0 · Reply
GoIrish1776
GoIrish1776 Nov. 6 at 2:44 PM
$NBIX Teva Pharmaceuticals CEO on earnings beat: Our shift to biopharma is working (Information on IRA discussion) https://www.cnbc.com/video/2025/11/05/teva-pharmaceuticals-ceo-on-earnings-beat-our-shift-to-biopharma-is-working.html
0 · Reply
GoIrish1776
GoIrish1776 Nov. 5 at 7:09 PM
$NBIX IRA impact on Teva explains it. AUSTEDO® – shows continued strong growth with global revenues of $618 million in Q3 2025 (+38% in LC YoY); led by U.S. revenue growth (+38% YoY). Increasing AUSTEDO 2025 revenue outlook by $50 million - $100 million to a new range of $2,050 million - $2,150 million. Inflation Reduction Act (IRA) price-setting reinforces confidence in our long-term outlook; on track for 2027 revenue target of >$2.5 billion and beyond 2027 peak year revenue target of >$3 billion.
1 · Reply
WestEgg
WestEgg Nov. 5 at 5:21 PM
$NBIX maybe ABBV is making a bid due to Cerevels failures.
1 · Reply
GoIrish1776
GoIrish1776 Nov. 5 at 3:31 PM
$NBIX Breakout! Run baby!
0 · Reply
PanicSeller8
PanicSeller8 Nov. 5 at 2:59 PM
$NBIX Why are we mooning and why don't I own more of this?
2 · Reply
FannyPackin
FannyPackin Nov. 5 at 2:52 PM
$NBIX YUGE, we finally gonna break 160 for new ATH here? I WANT 200!!
0 · Reply
BillionerOfKing
BillionerOfKing Nov. 5 at 2:33 PM
$NBIX Current Stock Price: $152.62 Contracts to trade: $155 NBIX Nov 21 2025 Call Entry: $1.84 Exit: $3.29 ROI: 78% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
CDMO
CDMO Nov. 5 at 2:31 PM
$NBIX 🤡🤡🤡
0 · Reply
marti837
marti837 Nov. 3 at 3:49 PM
$NBIX added
0 · Reply
JarvisFlow
JarvisFlow Nov. 3 at 3:37 PM
JP Morgan updates rating for Neurocrine Biosciences ( $NBIX ) to Overweight, target set at 191 → 183.
0 · Reply
JarvisFlow
JarvisFlow Nov. 3 at 3:31 PM
JP Morgan has updated their rating for Neurocrine Biosciences ( $NBIX ) to Overweight with a price target of 171.
0 · Reply
JarvisFlow
JarvisFlow Nov. 3 at 3:23 PM
JP Morgan has adjusted their stance on Neurocrine Biosciences ( $NBIX ), setting the rating to Overweight with a target price of 171 → 179.
0 · Reply
Halo202
Halo202 Nov. 2 at 10:01 PM
$NBIX $148+ by Friday
0 · Reply